Kessler Foundation, West Orange, New Jersey, USA.
Department of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
J Spinal Cord Med. 2021 Nov;44(6):886-895. doi: 10.1080/10790268.2021.1903140. Epub 2021 Apr 8.
CONTEXT/OBJECTIVES: Wheelchair users with chronic shoulder pain have few options after conservative treatments fail. This pilot study's purpose was to establish safety and treatment effects of micro-fragmented adipose tissue (MFAT) injections under ultrasound guidance for treatment of refractory shoulder pain caused by rotator cuff disease in wheelchair users with spinal cord injury (SCI) to prepare for a larger trial.
Pilot clinical trial.
Rehabilitation hospital outpatient clinic.
Ten wheelchair users with chronic SCI who had moderate-to-severe shoulder pain caused by refractory rotator cuff disease (diagnosed via ultrasound) for greater than 6 months.
Ultrasound-guided injections of MFAT into the pathologic rotator cuff tendons and other abnormal shoulder structures (e.g. acromioclavicular and glenohumeral joints; subacromial bursa).
6- and 12-month changes in 11-point Numerical Rating Scale (NRS); Wheelchair User's Shoulder Pain Index (WUSPI); Brief Pain Inventory pain interference items (BPI-I7); Patient Global Impression of Change (PGIC); ultrasound and physical exams; and adverse events.
There were no significant adverse events throughout the study period. WUSPI, NRS, and BPI-I7 scores were significantly lower 6 and 12 months post-procedure (P < .05). Of those who remained in the trial, clinically meaningful changes (≥30% decrease) in WUSPI, NRS, and BPI-I7 scores were observed in 77.8%, 77.8%, and 66.7% of participants, respectively. All but one participant reported improvement in clinical status. MFAT injection under ultrasound guidance is potentially a safe and efficacious treatment for refractory shoulder pain caused by rotator cuff disease in wheelchair users with SCI. A larger, randomized controlled trial has been initiated.: ClinicalTrials.gov identifier: NCT03167138.
背景/目的:慢性肩痛的轮椅使用者在保守治疗失败后选择有限。本研究旨在通过超声引导下微碎片脂肪组织(MFAT)注射,为脊髓损伤(SCI)轮椅使用者的肩袖疾病引起的难治性肩痛提供治疗选择,并为更大规模的试验做准备。
前瞻性临床试验。
康复医院门诊。
10 名慢性 SCI 轮椅使用者,因肩袖疾病(通过超声诊断)引起的慢性、中重度肩痛,持续时间大于 6 个月。
超声引导下将 MFAT 注射到病变的肩袖肌腱和其他异常肩结构(如肩锁关节和盂肱关节;肩峰下囊)。
11 分数字评分量表(NRS)6 个月和 12 个月的变化;轮椅使用者的肩痛指数(WUSPI);简明疼痛干扰量表(BPI-I7)的疼痛干扰项目;患者总体印象变化量表(PGIC);超声和体格检查;以及不良事件。
整个研究过程中没有出现明显的不良事件。WUSPI、NRS 和 BPI-I7 评分在治疗后 6 个月和 12 个月时显著降低(P < .05)。在继续参加试验的患者中,WUSPI、NRS 和 BPI-I7 评分的临床意义改善(下降≥30%)分别见于 77.8%、77.8%和 66.7%的患者。除 1 名患者外,所有患者均报告临床状况改善。超声引导下 MFAT 注射对 SCI 轮椅使用者的肩袖疾病引起的难治性肩痛可能是一种安全有效的治疗方法。一项更大规模的随机对照试验已经启动。临床Trials.gov 标识符:NCT03167138。